348 related articles for article (PubMed ID: 24841718)
1. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Kubota E; Williamson CT; Ye R; Elegbede A; Peterson L; Lees-Miller SP; Bebb DG
Cell Cycle; 2014; 13(13):2129-37. PubMed ID: 24841718
[TBL] [Abstract][Full Text] [Related]
2. 53BP1 depletion causes PARP inhibitor resistance in ATM-deficient breast cancer cells.
Hong R; Ma F; Zhang W; Yu X; Li Q; Luo Y; Zhu C; Jiang W; Xu B
BMC Cancer; 2016 Sep; 16(1):725. PubMed ID: 27613518
[TBL] [Abstract][Full Text] [Related]
3. Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.
Williamson CT; Kubota E; Hamill JD; Klimowicz A; Ye R; Muzik H; Dean M; Tu L; Gilley D; Magliocco AM; McKay BC; Bebb DG; Lees-Miller SP
EMBO Mol Med; 2012 Jun; 4(6):515-27. PubMed ID: 22416035
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitors target ATM+p53-defective gastric cancer.
Curtin NJ
Cell Cycle; 2014; 13(20):3161-2. PubMed ID: 25485492
[No Abstract] [Full Text] [Related]
5. Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.
Jette NR; Radhamani S; Arthur G; Ye R; Goutam S; Bolyos A; Petersen LF; Bose P; Bebb DG; Lees-Miller SP
Br J Cancer; 2019 Oct; 121(7):600-610. PubMed ID: 31481733
[TBL] [Abstract][Full Text] [Related]
6. Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells.
Lloyd RL; Wijnhoven PWG; Ramos-Montoya A; Wilson Z; Illuzzi G; Falenta K; Jones GN; James N; Chabbert CD; Stott J; Dean E; Lau A; Young LA
Oncogene; 2020 Jun; 39(25):4869-4883. PubMed ID: 32444694
[TBL] [Abstract][Full Text] [Related]
7. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition.
Gilardini Montani MS; Prodosmo A; Stagni V; Merli D; Monteonofrio L; Gatti V; Gentileschi MP; Barilà D; Soddu S
J Exp Clin Cancer Res; 2013 Nov; 32(1):95. PubMed ID: 24252502
[TBL] [Abstract][Full Text] [Related]
8. The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.
Weston VJ; Oldreive CE; Skowronska A; Oscier DG; Pratt G; Dyer MJ; Smith G; Powell JE; Rudzki Z; Kearns P; Moss PA; Taylor AM; Stankovic T
Blood; 2010 Nov; 116(22):4578-87. PubMed ID: 20739657
[TBL] [Abstract][Full Text] [Related]
9. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
Lin X; Chen D; Zhang C; Zhang X; Li Z; Dong B; Gao J; Shen L
J Exp Clin Cancer Res; 2018 Jun; 37(1):129. PubMed ID: 29954437
[TBL] [Abstract][Full Text] [Related]
10. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
Williamson CT; Muzik H; Turhan AG; Zamò A; O'Connor MJ; Bebb DG; Lees-Miller SP
Mol Cancer Ther; 2010 Feb; 9(2):347-57. PubMed ID: 20124459
[TBL] [Abstract][Full Text] [Related]
11. Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors.
Ji W; Weng X; Xu D; Cai S; Lou H; Ding L
Biochem Biophys Res Commun; 2020 Jan; 522(1):121-126. PubMed ID: 31753490
[TBL] [Abstract][Full Text] [Related]
12. PARP Inhibitor Olaparib Causes No Potentiation of the Bleomycin Effect in VERO Cells, Even in the Presence of Pooled ATM, DNA-PK, and LigIV Inhibitors.
Perini V; Schacke M; Liddle P; Vilchez-Larrea S; Keszenman DJ; Lafon-Hughes L
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167404
[TBL] [Abstract][Full Text] [Related]
13. Premature mitotic entry induced by ATR inhibition potentiates olaparib inhibition-mediated genomic instability, inflammatory signaling, and cytotoxicity in BRCA2-deficient cancer cells.
Schoonen PM; Kok YP; Wierenga E; Bakker B; Foijer F; Spierings DCJ; van Vugt MATM
Mol Oncol; 2019 Nov; 13(11):2422-2440. PubMed ID: 31529615
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of poly (ADP-ribose) polymerase inhibitor olaparib against head and neck cancer cells: Predictions of drug sensitivity based on PAR-p53-NF-κB interactions.
Kwon M; Jang H; Kim EH; Roh JL
Cell Cycle; 2016 Nov; 15(22):3105-3114. PubMed ID: 27686740
[TBL] [Abstract][Full Text] [Related]
15. Role of autophagy in chemoresistance: regulation of the ATM-mediated DNA-damage signaling pathway through activation of DNA-PKcs and PARP-1.
Yoon JH; Ahn SG; Lee BH; Jung SH; Oh SH
Biochem Pharmacol; 2012 Mar; 83(6):747-57. PubMed ID: 22226932
[TBL] [Abstract][Full Text] [Related]
16. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
[TBL] [Abstract][Full Text] [Related]
17. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib.
Wang C; Jette N; Moussienko D; Bebb DG; Lees-Miller SP
Transl Oncol; 2017 Apr; 10(2):190-196. PubMed ID: 28182994
[TBL] [Abstract][Full Text] [Related]
18. Promising Response of Olaparib in Patient With Germline
Chan KH; Rutazanaa D; Wray C; Thosani N; Yang V; Cen P
J Investig Med High Impact Case Rep; 2024; 12():23247096241240176. PubMed ID: 38504422
[TBL] [Abstract][Full Text] [Related]
19. Olaparib-induced Apoptosis Through EBNA1-ATR-p38 MAPK Signaling Pathway in Epstein-Barr Virus-positive Gastric Cancer Cells.
Moon SH; Park NS; Noh MH; Kim YS; Cheong SH; Hur DY
Anticancer Res; 2022 Jan; 42(1):555-563. PubMed ID: 34969765
[TBL] [Abstract][Full Text] [Related]
20. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
